Lifecore Biomedical, Inc. (LFCR) revenue and earnings history
Lifecore Biomedical, Inc. reported revenue of $129M for fiscal 2025 (year ended May 25, 2025), +0.5% on the year before, and net income of −$38.7M.
Over 15 years, from fiscal 2010 to fiscal 2025, revenue grew at a compound rate of −4.0% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended May 25, 2025 | $129M+0.5% | −$17.2M | −$38.7M | −$206K | $13.4M | −$13.6M | $10.2M | — | — | $8.27M | $130M | 10-K |
| 2024ended May 26, 2024 |
The latest quarter, insider trades and fund moves: Lifecore Biomedical, Inc. (LFCR) on OQRO.
Common questions
What was Lifecore Biomedical, Inc.'s revenue in fiscal 2025?
$129M for the year ended May 25, 2025, as reported in its 10-K filed Aug 7, 2025. That is +0.5% on fiscal 2024 ($128M).
How fast has Lifecore Biomedical, Inc.'s revenue grown?
From $238M in fiscal 2010 to $129M in fiscal 2025: a compound annual growth rate of −4.0% over 15 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Lifecore Biomedical, Inc. tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.